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Abstract Daily glatiramer acetate (GA) 20 mg/1.0 mL is
a ﬁrst-line treatment for relapsing-remitting multiple scle-
rosis (RRMS). To reduce the occurrence of injection pain
and local injection site reactions (LISRs), a reduced volume
formulation of GA was developed. This study compared
pain and LISRs after injecting the marketed and the novel
formulations. RRMS patients currently injecting GA
participated in this multicenter, randomized, crossover
comparative study. All patients administered once-daily
subcutaneous injections of GA 20 mg/1.0 mL (marketed
formulation) or GA 20 mg/0.5 mL (reduced volume for-
mulation) for 14 days. Patients were crossed-over to the
alternate treatment for an additional 14 days. Using a
Visual Analog Scale (VAS), patients recorded in daily
diaries the severity of injection pain immediately and 5 min
post-injection, and the presence and severity of LISRs
(swelling, redness, itching, lump) within 5 min and 24 h
post-injection. VAS pain scores were ranked signiﬁcantly
lower immediately and 5 min after GA 20 mg/0.5 mL
injections (p\0.0001). Although LISRs were rare for both
preparations, the severity of reactions ranked signiﬁcantly
lower and fewer symptoms occurred within 5 min and 24 h
of using the reduced volume formulation (p\0.0001). GA
injected subcutaneously in a reduced volume formulation is
a more tolerable option.
Keywords Relapsing-remitting multiple sclerosis 
Glatiramer acetate  Copaxone  Subcutaneous injections 
Local injection site reactions  Injection pain
Introduction
Glatiramer acetate (GA) injection (Copaxone, Teva Phar-
maceuticals Inc., Petah Tiqva, Israel) is indicated for
reducing the frequency of relapses in patients with relaps-
ing-remitting multiple sclerosis (RRMS), and in patients
who have experienced a ﬁrst clinical episode and have MRI
features consistent with multiple sclerosis (MS) [1]. This
ﬁrst-line treatment has proven efﬁcacy and safety [2–6]. As
with all therapeutics, patient adherence to the treatment
regimen is very important. Patients with chronic diseases
have lower drug adherence and persistence rates [7], with
studies of MS patients reporting that almost 40% of patients
with MS miss injections [8–10]. Many factors can lead to
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DOI 10.1007/s00415-010-5779-xpoor adherence with any medication [7]; patients have
reported that local injection site reactions (LISRs) and
injection site pain are a couple of the reasons why they miss
injections [10, 11].
LISRs, including pain, are the most common adverse
reactions reported by patients receiving GA [1]. In con-
trolled studies, the proportion of subjects reporting these
reactions at least once was higher following treatment with
GA than following placebo [2, 4, 5]. Although the etiology
of injection site pain is multi-factorial, an increase in the
volume of an injectable agent has been associated with
increased injection site pain [12]. A study assessing four
volumes of a subcutaneous injection found that increasing
the volume from 0.5 to 1.0 mL increased injection pain
signiﬁcantly [12]. In an attempt to potentially reduce the
occurrence of injection pain and other injection site reac-
tions, a reduced volume of the GA formulation was
developed. The new formulation contains 20 mg GA and
20 mg mannitol in 0.5 mL whereas the marketed formu-
lation contains 20 mg GA and 40 mg mannitol in 1.0 mL
solution. The objective of this study was to assess injection
pain and other LISRs associated with the reduced volume
formulation by comparing it to the marketed formulation.
Methods
Study design
The study was a multicenter, randomized, two-arm, single
crossover study designed to compare the tolerability and
safetyofGA20 mg/0.5 mLversusGA20 mg/1.0 mLwhen
administered subcutaneously by patients with RRMS. Dur-
ing the 7-day run-in period preceding the two treatment
periods, all patients administered a daily subcutaneous dose
of GA 20 mg/1.0 mL. During this period they were
instructed on a 7-site injection rotation, manual injection
techniques, and how to complete the patient diary. They
were also randomized at a ratio of 1:1 to one of two cross-
over sequences of either GA 20 mg/1.0 mL or GA 20 mg/
0.5 mL (Sequences 1 and 2) for the two treatment periods.
During the treatment periods, patients administered one of
the formulations of GA for 14 days and then the patients
were crossed-over to the alternate formulation for an addi-
tional 14-day treatment period. Total GA treatment duration
in the study was 5 weeks, including the 1-week run-in
period. Block randomization stratiﬁed by study site was
done according to a computer-generated schedule to ensure
that patients of each site were distributed equally between
the formulation sequences. Blinding in this study was not
possibleduetothepatients’abilitytodetectdifferenceinthe
volumes of each formulation. The study was conducted
following the principles of the Declaration of Helsinki, ICH
guidelinesongoodclinicalpractices,andallapplicablelaws
and regulations. All patients gave written informed consent
after the procedures had been fully explained, and prior to
performing any study related procedures.
Patients
Men or women, aged C18 years, with a diagnosis of RRMS
and taking GA 20 mg/1.0 mL per day subcutaneously with
the Autoject
2 for glass syringe or by a manual injection
technique for a minimum of 90 days were eligible for
inclusion. They also had to be willing to switch from using
an Autoject
2 for glass syringe to using a manual injection
technique or to continue with a manual injection technique
during the course of the study. Patients were excluded if in
the 30 days prior to screening (1) they were treated with
another immunomodulating therapy in conjunction with
GA, (2) they used intermittent or pulse courses of cortico-
steroids by any route of administration(corticosteroids were
prohibited for the duration of the study), or (3) used any
other parenteral medications. Patients with a presence or
history of skin necrosis or a known extensive dermatolog-
ical condition were excluded to prevent a potential con-
founding factor in the assessment of LISRs.
Treatments
During the 7-day run-in period preceding the two treatment
periods, all patients administered a daily subcutaneous dose
of GA 20 mg/1.0 mL. After the run-in period all patients
received once-daily subcutaneous administration of 20 mg
GA, as either 20 mg/1.0 mL or 20 mg/0.5 mL, for a 14-day
treatment period, and then received the second (alternate)
treatment as per the randomization schedule for an addi-
tional 14-day treatment period. Both the 20 mg/1.0 mL and
20 mg/0.5 mL formulations of GA have a pH range of
approximately 5.5–7.0 and are stable for up to 1 month at
room temperature with no adverse impact on product
potency, appearance, pH, clarity or other physicochemical
characteristics. All treatments were administered via a
manual injection technique. Compliance with the dosing
regimen for each period was determined by counting
returned unused study drug syringes.
Outcome measures
Using daily diaries, patients recorded the severity of pain
occurring immediately and 5 min after injection, and the
presence and severity of LISRs that occurred within 5 min
and 24 h post-injection. Daily diaries were collected at the
end of the run-in period, at the end of Treatment Period 1
(before they were crossed-over to Period 2), and at the end
of Treatment Period 2.
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between the two GA formulations in the total injection pain
rating occurring immediately after injection as reported on
a Visual Analog Scale (VAS). Daily injection pain was
rated by the patients with a 100 mm VAS, where 0 mm
represented ‘‘no pain’’ and 100 mm represented ‘‘worst
possible pain.’’ Injection pain occurring 5 min after the
injection was also recorded daily on a 100 mm VAS
(secondary outcome variable). Patients reported the pres-
ence or absence of LISRs and the degree of LISR severity
that occurred within the 5 min and 24 h periods following
the injection. LISR total presence scores could range from
0 to 4 for an individual patient depending on how many of
the following symptoms were experienced: redness, itch-
ing, swelling, and lump. LISR total severity scores could
range from 0 to 12 for an individual patient depending on
the severity (rated 0–3, with 0 = none to 3 = severe) of
each of the following symptoms experienced: redness,
itching, swelling, and lump.
Safety measures
Safetywasmonitoredateachstudysitebyassessingadverse
events (AEs), evaluating laboratory values (hematology,
chemistry, and urinalysis), conducting general physical
examinations, and conducting nervous system examinations
(including mental status, pupil and fundi, cranial nerves,
motor examination, gait, coordination, reﬂexes, and sensory
function).
Statistical analysis
The sample size (60 patients per group) was estimated to
provide 80% power of detecting an effect of size 18% with
a two-tailed t test for correlated sample means with an
alpha value of 0.05. Four trained individuals at a central
location measured the VAS ratings for all study patients
and calculated the patient daily scores (inter-rater consis-
tency was conﬁrmed). Daily scores within each period
were averaged to provide total pain ratings for each patient.
Also daily scores within each period for LISRs were
averaged to provide total LISR ratings.
All statistical analyses were performed using SAS

(SAS Institute Inc., Cary, NC), Version 8. The normality
assumption was checked using data plots and the Shapiro–
Wilk test for the primary clinical outcomes variable. Due to
the non-normality of the data, ANOVA with mean ranked
average scores and least square means (LS means) were
used to compare the treatment outcomes. The ANOVA
model for a two-treatment crossover study was run with
treatment, sequence, and period as ﬁxed effects, and patient
within sequence as a random effect. The corresponding
95% conﬁdence interval for treatment difference was
calculated. Descriptive statistics for continuous variables
consisted of n, mean, median, standard deviation (SD),
standard error of the mean (SEM), minimum, and maxi-
mum values. Statistical signiﬁcance was declared when
p\0.05.
Results
Patient characteristics
The study was conducted from July 2009 to September
2009. Patients were recruited from 21 centers in the United
States. A total of 148 patients were randomly assigned to
Sequence 1 (n = 76, Period 1: GA 20 mg/1.0 mL, Period
2: GA 20 mg/0.5 mL) or Sequence 2 (n = 72, Period 1:
GA 20 mg/0.5 mL, Period 2: GA 20 mg/1.0 mL). Nearly
all (95.9%, 142/148) of the patients completed the study.
Of the six patients who discontinued from the study,
ﬁve patients withdrew consent and one did not meet the
inclusioncriteriabutwasmistakenlyrandomized.Themajority
of patients (81.0%) were women, 90.5% of the population was
Caucasian, and the mean age was 46.0 years (Table 1). The
groupsreceivingSequence1andSequence2werecomparable
indemographiccharacteristics.Overall,99.5%ofpatientswere
compliant in the administration of 20 mg/0.5 mL GA and
99.6% of patients were compliant when administering the
20 mg/1.0 mL GA during the study.
Table 1 Patient demographics
Sequence 1
a
(n = 76)
Sequence 2
b
(n = 71)
Total
(N = 147)
Age (years)
Mean ± SD 45.1 ± 10.64 46.9 ± 9.64 46.0 ± 10.17
Median 45.0 48.0 47.0
Range 24–71 22–63 22–71
Gender, n (%)
Male 15 (19.7) 13 (18.3) 28 (19.0)
Female 61 (80.3) 58 (81.7) 119 (81.0)
Race, n (%)
Asian 0 (0.0) 1 (1.4) 1 (0.7)
Black or African
American
2 (2.6) 4 (5.6) 6 (4.1)
Caucasian 71 (93.4) 62 (87.3) 133 (90.5)
Other 3 (3.9) 4 (5.6) 7 (4.8)
SD Standard deviation
a Sequence 1: Period 1, GA 20 mg/1.0 mL; Period 2, GA 20 mg/
0.5 mL
b Sequence 2: Period 1, GA 20 mg/0.5 mL; Period 2, GA 20 mg/
1.0 mL
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The mean immediate VAS total pain score was 8.64 mm
after administration of 20 mg/0.5 mL GA and 11.89 mm
after administration of 20 mg/1.0 mL GA (Fig. 1). Because
of the non-normal distribution of the VAS scores, the rank
scores, rather than observed scores, were statistically
compared. LS mean ranked immediate VAS scores were
signiﬁcantly lower after administration of 20 mg/0.5 mL
GA than after 20 mg/1.0 mL GA (p\0.0001; LS mean
133.6, 95% CI 120.0–147.2; and LS mean 154.7, 95% CI
141.0–168.3; respectively). There were no signiﬁcant
effects associated with the treatment period or sequence of
formulation. Throughout the 14-day treatment period, the
daily mean immediate pain score was consistently lower
when the 20 mg/0.5 mL GA preparation was used than
when the 20 mg/1.0 mL GA preparation was used (Fig. 2).
Secondary outcomes
VAS pain score
As illustrated in Fig. 1, mean VAS total pain scores 5 min
after administration were 11.85 mm after the 20 mg/
0.5 mL GA preparation and 17.19 mm after the 20 mg/
1.0 mL GA preparation. The 20 mg/0.5 mL GA prepara-
tion was associated with signiﬁcantly less pain 5 min post-
injection than with the 20 mg/1.0 mL GA preparation; the
mean ranked VAS scores differed by 27.2 (p\0.0001; LS
mean 130.4, 95% CI 116.9–143.9; and LS mean 157.6,
95% CI 144.1–171.2; respectively). There were no signif-
icant effects associated with the treatment period or
sequence of formulation.
Presence of LISRs
When treated with 20 mg/0.5 mL GA the mean occurrence
(presence) of LISRs within 5 min post-injection was 1.41
symptoms (maximum four symptoms), whereas when
treated with 20 mg/1.0 mL GA the mean occurrence within
5 min post-injection was 1.85 symptoms (Fig. 3). As
indicated by the LS mean analysis for treatment effect, the
20 mg/0.5 mL GA preparation produced signiﬁcantly
fewer LISRs within 5 min post-injection than the 20 mg/
1.0 mL GA preparation (p\0.0001; mean ranked average
5 min LISR scores were 126.2 for the 20 mg/0.5 mL GA,
Fig. 1 VAS total pain scores (mean ? SEM) recorded immediately
and 5 min after injection of 20 mg/0.5 mL GA or 20 mg/1.0 mL GA.
aAs indicated on the Y axis, the rating scale for VAS total pain scores
was 0 ‘‘no pain’’ to 100 mm ‘‘worst possible pain.’’ *p\0.0001;
20 mg/0.5 mL LS mean 133.6 mm, 95% CI 120.0–147.2; and 20 mg/
1.0 mL LS mean 154.7 mm, 95% CI 141.0–168.3.
p\0.0001;
20 mg/0.5 mL LS mean 130.4 mm, 95% CI 116.9–143.9; and 20 mg/
1.0 mL LS mean 157.6 mm, 95% CI 144.1–171.2
Fig. 2 Daily mean (±SEM) immediate pain scores after injection of
20 mg/0.5 mL GA or 20 mg/1.0 mL GA.
aAs indicated on the Y axis,
the rating scale for VAS total pain scores was 0 ‘‘no pain’’ to 100 mm
‘‘worst possible pain.’’
Fig. 3 Mean (±SEM) occurrence of LISRs 5 min and 24 h after
injection of 20 mg/0.5 mL GA or 20 mg/1.0 mL GA.
aAs indicated
on the Y axis, the presence of symptoms scores could range from 0
‘‘no symptoms’’ to 4 ‘‘all four symptoms occurred.’’ *p\0.0001;
20 mg/0.5 mL LS mean 126.2 symptoms, 95% CI 112.9–139.6; and
20 mg/1.0 mL LS mean 161.3 symptoms, 95% CI 147.9–174.7.
p\0.0001; 20 mg/0.5 mL LS mean 132.0 symptoms, 95% CI
118.5–145.6; and 20 mg/1.0 mL LS mean 155.8 symptoms, 95% CI
142.2–169.3
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12395% CI 112.9–139.6 and 161.3 for the 20 mg/1.0 mL GA,
95% CI 147.9–174.7). Neither treatment period nor prep-
aration sequence affected the ﬁndings.
Within the 24-h time period, treatment with 20 mg/
0.5 mL GA was associated with a mean presence of 0.92
LISR symptoms, whereas treatment with 20 mg/1.0 mL
GA was associated with a mean presence of 1.19 LISR
symptoms (Fig. 3). As indicated by the LS mean for
treatment effect, the 20 mg/0.5 mL GA preparation pro-
duced signiﬁcantly fewer LISRs within 24 h post-injection
than the 20 mg/1.0 mL GA preparation (p\0.0001; mean
ranked scores were 132.0, 95% CI 118.5–145.6, and 155.8,
95% CI 142.2–169.3, respectively, no effects of treatment
period and formulation sequence).
Severity of LISRs
The mean LISR total severity score within 5 min after
administration was rated 1.64 for 20 mg/0.5 mL GA and
rated 2.30 for 20 mg/1.0 mL GA (Fig. 4, maximum score
could be 12). The 20 mg/0.5 mL GA preparation was
associated with a signiﬁcantly lower mean LISR symptom
severity score than the 20 mg/1.0 mL GA within 5 min
post-injection (p\0.0001; mean ranked scores were 125.3,
95% CI 112.0–138.6 and 162.2, 95% CI 148.9–175.6,
respectively, with no treatment period and formulation
sequence effects).
Within the 24-h time point, treatment with 20 mg/
0.5 mL GA was associated with a mean LISR severity
score of 1.10, whereas treatment with 20 mg/1.0 mL GA
was associated with a mean LISR severity score of 1.47
(Fig. 4). As indicated by the LS mean for treatment effect,
the 20 mg/0.5 mL GA preparation produced a signiﬁcantly
less severe mean LISR score within 24 h post-injection
than the 20 mg/1.0 mL GA preparation (p\0.0001; mean
ranked scores were 132.0, 95% CI 118.5–145.6 and 155.8,
95% CI 142.2–169.3, respectively, with no treatment per-
iod and formulation sequence effects).
No symptoms
Most patients reported some LISR symptoms within 5 min
following injection of either formulation. It is interesting to
note, though, that the percentage of patients reporting no
symptoms within 5 min of the 20 mg/0.5 mL GA injection
was twice the percentage of patients reporting no symp-
toms within 5 min of the 20 mg/1.0 mL GA (Fig. 5).
Likewise, within 24 h post-injections, the majority of
patients reported LISR symptoms; however, more patients
reported no symptoms after injecting 20 mg/0.5 mL GA
than after injecting 20 mg/1.0 mL GA (Fig. 5).
Fig. 4 Mean (±SEM) LISR total severity score 5 min and 24 h after
injection of 20 mg/0.5 mL GA or 20 mg/1.0 mL GA.
aAs indicated
on the Y axis, LISR total severity scores could range from 0 to 12 per
patient depending on the severity (0 ‘‘none’’ to 3 ‘‘severe’’) for each
of the four LISRs experienced: redness, itching, swelling and lump.
*p\0.0001; 20 mg/0.5 mL LS mean 125.3, 95% CI 112.0–138.6;
and 20 mg/1.0 mL LS mean 162.2, 95% CI 148.9–175.6.
p\0.0001; 20 mg/0.5 mL LS mean 132.0, 95% CI 118.5–145.6; and
20 mg/1.0 mL LS mean 155.8, 95% CI 142.2–169.3
Fig. 5 Percentage of patients
reporting no LISR symptoms
5 min and 24 h after injection of
20 mg/0.5 mL GA or 20 mg/
1.0 mL GA on days 0–3, days
4–6, days 7–9, and days[9
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Both formulations of GA were well tolerated. During the
study there were no deaths, serious adverse events (SAEs),
or AEs that lead to discontinuation. No signiﬁcant changes
in the laboratory parameters, vital signs, physical examina-
tions, or neurological examinations were noted compared
to baseline assessments or between formulations. The per-
centage of patients reporting AEs was low (\20%) for both
treatments. During the entire period of the study, 27 AEs
were reported for 18 (12.5%) patients treated with 20 mg/
1.0 mL GA, and 38 AEs were reported for 26 (18.1%)
patients treated with 20 mg/0.5 mL GA. The most fre-
quently reported AEs after administration of 20 mg/0.5 mL
GA were urinary tract infection (2.8%), viral upper respira-
tory tract infection (1.4%), arthralgia (1.4%), and headache
(1.4%). The most frequently reported AEs after adminis-
tration of 20 mg/1.0 mL GA were contusion (1.4%), mus-
cular weakness (1.4%), and ataxia (1.4%). Two severe AEs
were reported during the study: severe biliary dyskinesia
during the run-in period and severe hypertonia after admin-
istration of 20 mg/1.0 mL GA. Both events were not related
to the study treatment and resolved within 2 days. All other
AEs were either mild or moderate in intensity.
Treatment-related AEs were reported for two patients
during the run-in period (20 mg/1.0 mL GA): one patient
had biliary dyskinesia and one patient had presyncope.
Treatment-related AEs were reported for three patients
(2.1%) during the 20 mg/1.0 mL GA treatment period:
increased hepatic enzyme (n = 1), anxiety and panic attack
(n = 1 patient), and headache (n = 1). Similarly, treat-
ment-related AEs were reported for four patients (2.8%)
during the 20 mg/0.5 mL GA treatment period: headache
and injection site nodule (n = 1 patient), panic attack
(n = 1 patient), dyspnea (n = 1 patient), and constipation
(n = 1 patient). None of the treatment-related AEs were
severe in intensity.
Two AEs related to the injection-site were reported
during the study. One patient reported injection site
necrosis on day 2 of the run-in period. The event was mild
in intensity and not considered to be related to the study
treatment. Another patient reported injection site nodule on
day 1 of Period 1 of the 20 mg/0.5 mL GA treatment. The
event was mild in intensity, considered to be related to the
study treatment, and spontaneously resolved after 10 days.
Discussion
Overall, the results demonstrate a signiﬁcant improvement
in injection pain and LISRs (swelling, redness, itching, and
lump) with the novel formulation compared with the
marketed formulation. The mean pain scores were low for
both formulations; however, the mean immediate VAS
total pain score was signiﬁcantly lower after administration
of 20 mg/0.5 mL GA injection compared with the 20 mg/
1.0 mL GA injection. The lower immediate VAS pain
score associated with the novel formulation was consistent
over all 14 days of the study, indicating that the
improvement in injection pain did not diminish over time.
The reduced VAS pain score associated with the novel
formulation was also evident 5 min post-injection.
TheinitialonsetofLISRsexperiencedbypatientscanlead
them to discontinue treatment or miss injections. With the
realization that LISRs may lead to non-adherence, research-
ers have been investigating ways to limit LISRs [13, 14]. Use
of warm compresses and rotating the injection site seem to
have a moderate effect [13]. As evidenced by the present
study, reducing the volume may also provide a moderate
beneﬁt. The incidence and severity of LISRs within 5 min
and 24 h post-injection were signiﬁcantly less for the novel
formulation than the marketed formulation. Moreover, even
though most patients reported some LISRs following injec-
tion of either formulation, a greater percentage of patients
treated with the reduced volume solution reported no symp-
toms within 5 min and 24 h after injection. A longer study
duration would be needed to determine whether the improve-
ment in injection pain and LISRs associated with the novel
formulation improvesquality of life, incidence oflipoatrophy,
and long-term drug adherence.
A limitation of the study is that it was not blinded.
Although blinding of the administered volume of the dose
represents a superior experimental design, it was not pos-
sible to implement in the present trial for several reasons.
First, the patients would have been required to be seen at
the clinic every day, for a total of 35 days, to receive their
injection. It would have been logistically very difﬁcult for
the large number of patients required for this trial, and
place too great a burden on these patients to undertake
daily visits. Second, to blind the volume of the formulation
in the syringe, it would not have been sufﬁcient to cover
the syringe with opaque tape, or use a syringe with opaque
glass, as the differences in the length of the syringe plun-
ger, related to differences in the volume, would have been
noticed by the patients. A new syringe with a redesigned
plunger was not available for this study. However, it is
important to note that, although the patients were able to
detect a difference in the volume of the formulation, the
trial investigators took care not to present one formulation
as ‘‘better’’ or ‘‘superior’’ than the other formulation. In
addition, patient diaries were collected after each period of
the trial so that patients did not have the results of the
previous entries for comparison purposes.
Both formulations had a good tolerability and safety
proﬁle. The percentage of subjects reporting AEs was
low (\20%) for both treatments. All AEs were reported
1922 J Neurol (2010) 257:1917–1923
123previously and there were no unexpected laboratory values.
The novel formulation has the potential to improve patient
adherence by producing less pain, and fewer and less
severe LISRs. The 20 mg/0.5 mL formulation is a more
tolerable option for patients using subcutaneous injections
of GA. Since injection site reactions, including pain, are
the most frequently reported AEs in subjects receiving
daily injections of GA for RRMS, the 20 mg/0.5 mL for-
mulation may offer clinical beneﬁts for patients.
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